Unknown

Dataset Information

ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer.


ABSTRACT:

Background

In colorectal cancer (CRC), BRAF mutations influence tumour progression. In mismatch repair-deficient (dMMR) tumours, BRAF mutations are associated with a good prognosis, whereas in MMR-competent tumours, they are detrimental. The differential expression of the downstream MAPK pathway members, which are constitutively activated in BRAF mutant patients, may account for these differences.

Methods

Phosphorylation of ERK, p38MAPK and JNK was assessed by immunohistochemistry, utilising CRC tissue microarrays. A discovery cohort (n = 187) and a validation cohort (n = 801) were analysed for associations with BRAF mutations, clinicopathological characteristics and cancer-specific survival (CSS).

Results

In 801 CRC patients, nuclear ERK phosphorylation (HR 0.65 95%

SUBMITTER: Roseweir AK 

PROVIDER: S-EPMC6070918 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature